Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GABRP | O00591 | 2/20 | 0.36 |
| ▸ | GABRD | O14764 | 2/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.36 |
| ▸ | GABRE | P78334 | 2/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.36 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.36 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.36 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptaminol SCHEMBL152610 | 0.97 | OPRM1 (0.46) | OPRM1ALDH1A1TDP1TP53GABRP | |
| Heptaminol SCHEMBL7530730 | 0.97 | OPRM1 (0.46) | OPRM1ALDH1A1TDP1TP53GABRP | |
| Heptaminol SCHEMBL3163491 | 0.97 | OPRM1 (0.46) | OPRM1ALDH1A1TDP1TP53GABRP | |
| Heptaminol SCHEMBL317122 | 0.95 | OPRM1 (0.44) | OPRM1ALDH1A1TDP1TP53GABRP | |
| Heptaminol SCHEMBL1649354 | 0.93 | OPRM1 (0.42) | OPRM1ALDH1A1TDP1TP53GABRP | |
| SCHEMBL10184723 | 0.93 | OPRM1 (0.48) | OPRM1ALDH1A1TDP1TP53GABRP | |
| Heptaminol SCHEMBL28891669 | 0.87 | OPRM1 (0.38) | OPRM1ALDH1A1TDP1TP53GABRP | |
| Heptaminol SCHEMBL11141578 | 0.85 | TP53 (0.52) | OPRM1ALDH1A1TDP1TP53GABRP | |
| SCHEMBL3154871 | 0.84 | — | — | |
| SCHEMBL25703625 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585850-B2 | Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases | ADENOBIO N.V. (NL) | 2009-09-08 | — | — | US | disclosed |
| WO-2005074946-A1 | STABLE AND ACTIVE COMPLEXES OF ADENOSINE AND ADENOSINE PHOSPHATES WITH AMINOALCOHOLS FOR THE TREATMENT OF PULMONARY ARTERY HYPERTENSION, CARDIAC FAILURE AND OTHER DISEASES | ADENOBIO N.V. (NL) | 2005-08-18 | — | — | WO | disclosed |
| US-20050176675-A1 | Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases | ADENOBIO N.V. (NL) | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176675-A1 | Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases | ADK, ADORA3, ADORA1 | OPRM1 3921/4885ALDH1A1 1498/4885TDP1 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.